Advice
Following a full resubmission.
Nicotinic acid modified release tablets (Niaspan®) is not recommended for use in NHS Scotland for the treatment of dyslipidaemia and primary hypercholesterolaemia as monotherapy in patients who do not tolerate HMG-CoA reductase inhibitors and is not recommended for use when prescribed in combination with HMG-CoA reductase inhibitors (statins).
There is evidence that nicotinic acid modified release tablets lowers LDL cholesterol levels to a small extent and raises HDL-cholesterol levels to a greater extent. However the evidence for use in combination with HMG-CoA reductase inhibitors is less convincing. The economic case for use as monotherapy or co-therapy in the licensed indication was not demonstrated.
Download detailed advice53KB (PDF)
Medicine details
- Medicine name:
- Nicotinic acid modified release tablet (Niaspan®)
- SMC ID:
- 93/04
- Indication:
- Dyslipidaemia
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 10 January 2005